Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P030017/S396

WaveWriter Alpha and WaveWriter Alpha Prime SCS Systems; Celestia and Celestia Prime SCS Systems

Boston Scientific Corp · Decision date Sep 9, 2026

FDA DECISIONP030017/S396

What did the FDA approve?

FDA records P030017/S396 as a supplement to PMA P030017, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Sep 9, 2026.

FDA approval order statement

the removal of the precaution statement related to subperception therapy in the Information for Prescribers and Information for Patients user manuals for the WaveWriter Alpha, WaveWriter Alpha Prime, Celestia, and Celestia Prime Spinal Cord Stimulation (SCS) Systems.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Neurology
Decision date
Sep 9, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P030017/S396
Regulatory pathway
PMA supplement
Product code
LGW
Decision code
APPR
Decision date
Sep 9, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.

Product code
LGW
FDA device class
3

For the original device and its historical approval scope, see PMA P030017. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P030017 · Original PMA

    PRECISION SPINAL CORD STIMULATION(SCS) SYSTEM

  2. P030017/S396 received

    Application receipt date recorded by FDA.

  3. P030017/S396 · FDA decision

    Normal 180 Day Track

  4. P030017/S399 · Related supplement

    Precision Spectra SCS Systems; Precision Novi SCS Systems; Precision Montage MRI SCS Systems; Spectra Wave Writer SCS Sy

Timeline entries are records held by MedtechLedger for P030017. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P030017

Explore the linked device profile

Other records with product code LGW

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corp

Headquarters
Not reported
FDA applicant address
25155 Rye Canyon Loop, Valencia, CA, 91355

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records